Literature DB >> 28105181

Activator protein 1 promotes gemcitabine-induced apoptosis in pancreatic cancer by upregulating its downstream target Bim.

Xiaoxia Ren1, Wenjing Zhao1, Yongxing Du1, Taiping Zhang1, Lei You1, Yupei Zhao1.   

Abstract

Gemcitabine is a commonly used chemotherapy drug in pancreatic cancer. The function of activator protein 1 (AP-1) is cell-specific, and its function depends on the expression of other complex members. In the present study, we added gemcitabine to the media of Panc-1 and SW1990 cells at clinically achieved concentrations (10 µM). Compared with constitutive c-Fos expression, c-Jun expression increased in a dose-dependent manner upon gemcitabine treatment. c-Jun overexpression increased gemcitabine-induced apoptosis through Bim activation, while cell apoptosis and Bim expression decreased following c-Jun knockdown. Furthermore, gemcitabine-induced apoptosis and Bim levels decreased when c-Jun phosphorylation was blocked by SP600125. Our findings suggest that c-Jun, which is a member of the AP-1 complex, functions in gemcitabine-induced apoptosis by regulating its downstream target Bim in pancreatic cancer cells.

Entities:  

Keywords:  Bim; activator protein 1; apoptosis; c-Jun; gemcitabine

Year:  2016        PMID: 28105181      PMCID: PMC5228527          DOI: 10.3892/ol.2016.5294

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  41 in total

1.  The effect of c-Fos demethylation on sodium fluoride-induced apoptosis in L-02 cells.

Authors:  Qiang Niu; HongLiang Liu; ZhiZhong Guan; Qiang Zeng; ShuXia Guo; Ping He; LiJuan Guo; Ping Gao; BaYi Xu; ZhiXia Xu; Tao Xia; AiGuo Wang
Journal:  Biol Trace Elem Res       Date:  2012-04-18       Impact factor: 3.738

Review 2.  Treatment of metastatic pancreatic adenocarcinoma: a review.

Authors:  Ramya Thota; James M Pauff; Jordan D Berlin
Journal:  Oncology (Williston Park)       Date:  2014-01       Impact factor: 2.990

Review 3.  Key cancer cell signal transduction pathways as therapeutic targets.

Authors:  Roberto Bianco; Davide Melisi; Fortunato Ciardiello; Giampaolo Tortora
Journal:  Eur J Cancer       Date:  2006-01-11       Impact factor: 9.162

4.  Activation of c-Jun NH2-terminal kinase is required for gemcitabine's cytotoxic effect in human lung cancer H1299 cells.

Authors:  Fuminori Teraishi; Lidong Zhang; Wei Guo; Fengqin Dong; John J Davis; Anning Lin; Bingliang Fang
Journal:  FEBS Lett       Date:  2005-11-14       Impact factor: 4.124

5.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Authors:  Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux
Journal:  N Engl J Med       Date:  2011-05-12       Impact factor: 91.245

Review 6.  Medical treatment of pancreatic cancer: new hopes after 10 years of gemcitabine.

Authors:  Isabelle Trouilloud; Olivier Dubreuil; Tarek Boussaha; Céline Lepère; Bruno Landi; Aziz Zaanan; Jean-Baptiste Bachet; Julien Taieb
Journal:  Clin Res Hepatol Gastroenterol       Date:  2011-03-23       Impact factor: 2.947

7.  Down-regulation of c-fos by shRNA sensitizes adriamycin-resistant MCF-7/ADR cells to chemotherapeutic agents via P-glycoprotein inhibition and apoptosis augmentation.

Authors:  Ruizan Shi; Hongwei Peng; Xiangfei Yuan; Xiuli Zhang; Yanjun Zhang; Dongmei Fan; Xuyi Liu; Dongsheng Xiong
Journal:  J Cell Biochem       Date:  2013-08       Impact factor: 4.429

8.  Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate.

Authors:  Caio M Rocha Lima; Mark R Green; Robert Rotche; Wilson H Miller; G Mark Jeffrey; Laura A Cisar; Adele Morganti; Nicoletta Orlando; Gabriela Gruia; Langdon L Miller
Journal:  J Clin Oncol       Date:  2004-09-15       Impact factor: 44.544

9.  Genome-wide profiling of AP-1-regulated transcription provides insights into the invasiveness of triple-negative breast cancer.

Authors:  Chunyan Zhao; Yichun Qiao; Philip Jonsson; Jian Wang; Li Xu; Pegah Rouhi; Indranil Sinha; Yihai Cao; Cecilia Williams; Karin Dahlman-Wright
Journal:  Cancer Res       Date:  2014-05-15       Impact factor: 12.701

10.  Erlotinib-cisplatin combination inhibits growth and angiogenesis through c-MYC and HIF-1α in EGFR-mutated lung cancer in vitro and in vivo.

Authors:  Jasmine G Lee; Reen Wu
Journal:  Neoplasia       Date:  2015-02       Impact factor: 5.715

View more
  2 in total

1.  lncRNA RP11-147L13.8 suppresses metastasis and chemo-resistance by modulating the phosphorylation of c-Jun protein in GBC.

Authors:  Bohao Zheng; Jiwen Wang; Kun Fan; Wentao Sun; Wenze Wan; Zhihui Gao; Xiaojian Ni; Dexiang Zhang; Xiaoling Ni; Tao Suo; Han Liu; Houbao Liu; Sheng Shen
Journal:  Mol Ther Oncolytics       Date:  2021-09-03       Impact factor: 7.200

2.  The Olive Biophenols Oleuropein and Hydroxytyrosol Selectively Reduce Proliferation, Influence the Cell Cycle, and Induce Apoptosis in Pancreatic Cancer Cells.

Authors:  Chloe D Goldsmith; Danielle R Bond; Helen Jankowski; Judith Weidenhofer; Costas E Stathopoulos; Paul D Roach; Christopher J Scarlett
Journal:  Int J Mol Sci       Date:  2018-07-02       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.